Page last updated: 2024-12-07

rhc 3164

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-chloro-5-propyl-1,2,4-triazolo(4,3-a)quinoxaline-1,4(2H,5H)-dione: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133527
CHEMBL ID121101
MeSH IDM0120009

Synonyms (9)

Synonym
rev 3164
(1,2,4)triazolo(4,3-a)quinoxaline-1,4(2h,5h)-dione, 7-chloro-5-propyl-
7-chloro-5-propyl-1,2,4-triazolo(4,3-a)quinoxaline-1,4(2h,5h)-dione
rhc-3164
rev-3164
rhc 3164
CHEMBL121101
80708-33-4
DTXSID90230516

Research Excerpts

Effects

ExcerptReferenceRelevance
"RHC 3164 has been investigated for its antiallergic activities in 3 in vitro models of anaphylaxis. "( Antiallergic activity profiles in vitro of RHC 3164 and related compounds. II. Comparison of RHC 3164 with disodium cromoglycate.
Dally-Meade, V; Huang, F; Jariwala, N; Khandwala, A, 1984
)
1.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID185586Percent inhibitory activity in rat passive cutaneous anaphylaxis test at a dose of 25 mg/kg administered perorally1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents.
AID1859262Inhibition of IgE-mediated passive cutaneous anaphylaxis in rat when administered orally2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID1859261Inhibition of IgE-mediated passive cutaneous anaphylaxis in rat at 25 mg/kg, po2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID181354Concentration required to inhibit Antigen-induced release of Histamine from rat mast cells1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents.
AID1859258Inhibition of antigen-induced release of histamine (AIR) from rat peritoneal mast cells (RMC)2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID177829Effective dose against IgE-mediated cutaneous anaphylaxis in the rat after peroral administration1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]